{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:41:15Z","timestamp":1790152875455,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02096-2","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T02:02:38Z","timestamp":1681956158000},"page":"2399-2409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8899-684X","authenticated-orcid":false,"given":"R. M.","family":"Ruggeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. C.","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alibrandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Santarpia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"2096_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10555-011-9280-5","volume":"30","author":"TJ Stewart","year":"2011","unstructured":"Stewart TJ, Smyth MJ (2011) Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 30:125\u2013140. https:\/\/doi.org\/10.1007\/s10555-011-9280-5","journal-title":"Cancer Metastasis Rev"},{"key":"2096_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"2096_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B (2021) Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 23:39. https:\/\/doi.org\/10.1208\/s12248-021-00574-0","journal-title":"AAPS J"},{"key":"2096_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV, Investigators R (2022) Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386:24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970","journal-title":"N Engl J Med"},{"key":"2096_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010246","author":"CC Spagnolo","year":"2022","unstructured":"Spagnolo CC, Giuffrida G, Cannavo S, Franchina T, Silvestris N, Ruggeri RM, Santarpia M (2022) Management of endocrine and metabolic toxicities of immune-checkpoint inhibitors: from clinical studies to a real-life scenario. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15010246","journal-title":"Cancers (Basel)"},{"key":"2096_CR6","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974\u20131982. https:\/\/doi.org\/10.1200\/JCO.2014.59.4358","journal-title":"J Clin Oncol"},{"key":"2096_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"2096_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173\u2013182. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"2096_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5301\/tj.5000625","volume":"103","author":"A Inno","year":"2017","unstructured":"Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, Gori S (2017) Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori 103:405\u2013421. https:\/\/doi.org\/10.5301\/tj.5000625","journal-title":"Tumori"},{"key":"2096_CR10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","volume":"25","author":"J Del Rivero","year":"2020","unstructured":"Del Rivero J, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL (2020) Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management. Oncologist 25:290\u2013300. https:\/\/doi.org\/10.1634\/theoncologist.2018-0470","journal-title":"Oncologist"},{"key":"2096_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40:17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"2096_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","volume":"42","author":"RM Ruggeri","year":"2019","unstructured":"Ruggeri RM, Campenni A, Giuffrida G, Trimboli P, Giovanella L, Trimarchi F, Cannavo S (2019) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest 42:745\u2013756. https:\/\/doi.org\/10.1007\/s40618-018-0984-z","journal-title":"J Endocrinol Invest"},{"key":"2096_CR13","doi-asserted-by":"publisher","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","volume":"106","author":"CA Muir","year":"2021","unstructured":"Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM (2021) Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 106:e3704\u2013e3713. https:\/\/doi.org\/10.1210\/clinem\/dgab263","journal-title":"J Clin Endocrinol Metab"},{"key":"2096_CR14","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00262-022-03151-2","volume":"71","author":"MS von Itzstein","year":"2022","unstructured":"von Itzstein MS, Gonugunta AS, Wang Y, Sheffield T, Lu R, Ali S, Fattah FJ, Xie D, Cai J, Xie Y, Gerber DE (2022) Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 71:2169\u20132181. https:\/\/doi.org\/10.1007\/s00262-022-03151-2","journal-title":"Cancer Immunol Immunother"},{"key":"2096_CR15","doi-asserted-by":"publisher","first-page":"886930","DOI":"10.3389\/fendo.2022.886930","volume":"13","author":"CA Muir","year":"2022","unstructured":"Muir CA, Tsang VHM, Menzies AM, Clifton-Bligh RJ (2022) Immune related adverse events of the thyroid\u2014a narrative review. Front Endocrinol (Lausanne) 13:886930. https:\/\/doi.org\/10.3389\/fendo.2022.886930","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2096_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1089\/thy.2018.0116","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R (2018) Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid 28:1243\u20131251. https:\/\/doi.org\/10.1089\/thy.2018.0116","journal-title":"Thyroid"},{"key":"2096_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22:886\u2013894. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res"},{"key":"2096_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40618-019-01112-8","volume":"43","author":"EM Presotto","year":"2020","unstructured":"Presotto EM, Rastrelli G, Desideri I, Scotti V, Gunnella S, Pimpinelli N, Vaccher E, Bearz A, Di Costanzo F, Bruggia M, Mini E, Maggi M, Peri A (2020) Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. J Endocrinol Invest 43:337\u2013345. https:\/\/doi.org\/10.1007\/s40618-019-01112-8","journal-title":"J Endocrinol Invest"},{"key":"2096_CR19","doi-asserted-by":"publisher","first-page":"101411","DOI":"10.1016\/j.beem.2020.101411","volume":"34","author":"R Percik","year":"2020","unstructured":"Percik R, Shoenfeld Y (2020) Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to? Best Pract Res Clin Endocrinol Metab 34:101411. https:\/\/doi.org\/10.1016\/j.beem.2020.101411","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2096_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12020-021-02750-w","volume":"74","author":"R Rubino","year":"2021","unstructured":"Rubino R, Marini A, Roviello G, Presotto EM, Desideri I, Ciardetti I, Brugia M, Pimpinelli N, Antonuzzo L, Mini E, Livi L, Maggi M, Peri A (2021) Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. Endocrine 74:172\u2013179. https:\/\/doi.org\/10.1007\/s12020-021-02750-w","journal-title":"Endocrine"},{"key":"2096_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081944","author":"M Peiffert","year":"2021","unstructured":"Peiffert M, Cugnet-Anceau C, Dalle S, Chikh K, Assaad S, Disse E, Raverot G, Borson-Chazot F, Abeillon-du Payrat J (2021) Graves\u2019 disease during immune checkpoint inhibitor therapy (a case series and literature review). Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13081944","journal-title":"Cancers (Basel)"},{"key":"2096_CR22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","volume":"31","author":"J Haanen","year":"2020","unstructured":"Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA, Obeid M (2020) Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol 31:724\u2013744. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.285","journal-title":"Ann Oncol"},{"key":"2096_CR23","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.13297","volume":"86","author":"DL Morganstein","year":"2017","unstructured":"Morganstein DL, Lai Z, Spain L, Diem S, Levine D, Mace C, Gore M, Larkin J (2017) Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86:614\u2013620. https:\/\/doi.org\/10.1111\/cen.13297","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2096_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1530\/EJE-17-0810","volume":"178","author":"ES Scott","year":"2018","unstructured":"Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH (2018) The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol 178:173\u2013180. https:\/\/doi.org\/10.1530\/EJE-17-0810","journal-title":"Eur J Endocrinol"},{"key":"2096_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40618-017-0772-1","volume":"41","author":"F Guaraldi","year":"2018","unstructured":"Guaraldi F, La Selva R, Sama MT, D\u2019Angelo V, Gori D, Fava P, Fierro MT, Savoia P, Arvat E (2018) Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest 41:549\u2013556. https:\/\/doi.org\/10.1007\/s40618-017-0772-1","journal-title":"J Endocrinol Invest"},{"key":"2096_CR26","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M (2017) Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102:2770\u20132780. https:\/\/doi.org\/10.1210\/jc.2017-00448","journal-title":"J Clin Endocrinol Metab"},{"key":"2096_CR27","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.21873\/invivo.11166","volume":"31","author":"T Maekura","year":"2017","unstructured":"Maekura T, Naito M, Tahara M, Ikegami N, Kimura Y, Sonobe S, Kobayashi T, Tsuji T, Minomo S, Tamiya A, Atagi S (2017) Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer. In Vivo 31:1035\u20131039. https:\/\/doi.org\/10.21873\/invivo.11166","journal-title":"In Vivo"},{"key":"2096_CR28","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s40618-021-01508-5","volume":"44","author":"C Luongo","year":"2021","unstructured":"Luongo C, Morra R, Gambale C, Porcelli T, Sessa F, Matano E, Damiano V, Klain M, Schlumberger M, Salvatore D (2021) Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy. J Endocrinol Invest 44:1927\u20131933. https:\/\/doi.org\/10.1007\/s40618-021-01508-5","journal-title":"J Endocrinol Invest"},{"key":"2096_CR29","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1089\/thy.2019.0726","volume":"30","author":"EA Basak","year":"2020","unstructured":"Basak EA, van der Meer JWM, Hurkmans DP, Schreurs MWJ, Oomen-de Hoop E, van der Veldt AAM, Bins S, Joosse A, Koolen SLW, Debets R, Peeters RP, Aerts J, Mathijssen RHJ, Medici M (2020) Overt thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients. Thyroid 30:966\u2013973. https:\/\/doi.org\/10.1089\/thy.2019.0726","journal-title":"Thyroid"},{"key":"2096_CR30","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","volume":"44","author":"L Brilli","year":"2021","unstructured":"Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabro L, Pilli T, Cartocci A, Pacini F, Di Giacomo AM, Castagna MG (2021) Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest 44:1719\u20131726. https:\/\/doi.org\/10.1007\/s40618-020-01480-6","journal-title":"J Endocrinol Invest"},{"key":"2096_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7495","author":"Y Yasuda","year":"2021","unstructured":"Yasuda Y, Iwama S, Sugiyama D, Okuji T, Kobayashi T, Ito M, Okada N, Enomoto A, Ito S, Yan Y, Sugiyama M, Onoue T, Tsunekawa T, Ito Y, Takagi H, Hagiwara D, Goto M, Suga H, Banno R, Takahashi M, Nishikawa H, Arima H (2021) CD4(+) T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abb7495","journal-title":"Sci Transl Med"},{"key":"2096_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","volume":"75","author":"R Gutzmer","year":"2017","unstructured":"Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pfohler C, Gesierich A, Livingstone E, Satzger I, Kahler KC, German Dermatooncology G (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75:24\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.038","journal-title":"Eur J Cancer"},{"key":"2096_CR33","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905\u20131912. https:\/\/doi.org\/10.1200\/JCO.2017.77.0305","journal-title":"J Clin Oncol"},{"key":"2096_CR34","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","volume":"67","author":"KC Kahler","year":"2018","unstructured":"Kahler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, Meiss F, Pfohler C, Schlaak M, Terheyden P, Thoms KM, Ziemer M, Zimmer L, Gutzmer R, German Dermatologic Cooperative Oncology G (2018) Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother 67:825\u2013834. https:\/\/doi.org\/10.1007\/s00262-018-2134-z","journal-title":"Cancer Immunol Immunother"},{"key":"2096_CR35","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00262-021-02851-5","volume":"70","author":"S Hoa","year":"2021","unstructured":"Hoa S, Laaouad L, Roberts J, Ennis D, Ye C, Al Jumaily K, Pope J, Nevskaya T, Saltman A, Himmel M, Rottapel R, Ly C, Colmegna I, Fifi-Mah A, Maltez N, Tisseverasinghe A, Hudson M, Jamal S (2021) Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian research group of rheumatology in immuno-oncology. Cancer Immunol Immunother 70:2197\u20132207. https:\/\/doi.org\/10.1007\/s00262-021-02851-5","journal-title":"Cancer Immunol Immunother"},{"key":"2096_CR36","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1097\/RHU.0000000000001777","volume":"28","author":"N Ghosh","year":"2022","unstructured":"Ghosh N, Chan KK, Jivanelli B, Bass AR (2022) Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review. J Clin Rheumatol 28:e498\u2013e505. https:\/\/doi.org\/10.1097\/RHU.0000000000001777","journal-title":"J Clin Rheumatol"},{"key":"2096_CR37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3389\/fendo.2018.00813","volume":"9","author":"C Iadarola","year":"2019","unstructured":"Iadarola C, Croce L, Quaquarini E, Teragni C, Pinto S, Bernardo A, Fonte R, Marin\u00f2 M, Rotondi M, Chiovato L (2019) Nivolumab induced thyroid dysfunction: unusual clinical presentation and challenging diagnosis. Front Endocrinol (Lausanne) 9:813. https:\/\/doi.org\/10.3389\/fendo.2018.00813","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2096_CR38","doi-asserted-by":"publisher","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","volume":"14","author":"I Yamauchi","year":"2019","unstructured":"Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R, Kitamura M, Kitawaki T, Hishizawa M, Kawaguchi-Sakita N, Fujii T, Taura D, Sone M, Inagaki N (2019) Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE 14:e0216954. https:\/\/doi.org\/10.1371\/journal.pone.0216954","journal-title":"PLoS ONE"},{"key":"2096_CR39","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/cas.14363","volume":"111","author":"C Kurimoto","year":"2020","unstructured":"Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, Takeshima K, Furukawa Y, Morita S, Yamamoto Y, Yamashita S, Katsuda M, Hayata A, Akamatsu H, Jinnin M, Hara I, Yamaue H, Akamizu T (2020) Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci 111:1468\u20131477. https:\/\/doi.org\/10.1111\/cas.14363","journal-title":"Cancer Sci"},{"key":"2096_CR40","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","volume":"7","author":"HI Kim","year":"2017","unstructured":"Kim HI, Kim M, Lee SH, Park SY, Kim YN, Kim H, Jeon MJ, Kim TY, Kim SW, Kim WB, Kim SW, Lee DH, Park K, Ahn MJ, Chung JH, Shong YK, Kim WG, Kim TH (2017) Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology 7:e1375642. https:\/\/doi.org\/10.1080\/2162402X.2017.1375642","journal-title":"Oncoimmunology"},{"key":"2096_CR41","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4:374\u2013378. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925","journal-title":"JAMA Oncol"},{"key":"2096_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Kottschade L, Ryder M (2020) PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 30:177\u2013184. https:\/\/doi.org\/10.1089\/thy.2019.0250","journal-title":"Thyroid"},{"key":"2096_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","volume":"70","author":"J Lima Ferreira","year":"2021","unstructured":"Lima Ferreira J, Costa C, Marques B, Castro S, Victor M, Oliveira J, Santos AP, Sampaio IL, Duarte H, Marques AP, Torres I (2021) Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunol Immunother 70:299\u2013309. https:\/\/doi.org\/10.1007\/s00262-020-02664-y","journal-title":"Cancer Immunol Immunother"},{"key":"2096_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2019.12.014","volume":"140","author":"E Baldini","year":"2020","unstructured":"Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, Ceresoli GL, Illiano A, Verderame F, Fasola G, Ricevuto E, Marchetti P, Pinto C, Carteni G, Scotti V, Tibaldi C, Fioretto L, Giannarelli D (2020) Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: the Italian NSCLC expanded access program. Lung Cancer 140:59\u201364. https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.014","journal-title":"Lung Cancer"},{"key":"2096_CR45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","volume":"145","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145:479\u2013485. https:\/\/doi.org\/10.1007\/s00432-018-2805-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"2096_CR46","doi-asserted-by":"publisher","first-page":"2017162","DOI":"10.1080\/2162402X.2021.2017162","volume":"11","author":"D Hsiehchen","year":"2022","unstructured":"Hsiehchen D, Naqash AR, Espinoza M, Von Itzstein MS, Cortellini A, Ricciuti B, Owen DH, Laharwal M, Toi Y, Burke M, Xie Y, Gerber DE (2022) Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology 11:2017162. https:\/\/doi.org\/10.1080\/2162402X.2021.2017162","journal-title":"Oncoimmunology"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02096-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02096-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02096-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T01:10:10Z","timestamp":1696641010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02096-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02096-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"4 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patients were treated and followed according to international guidelines and local practices. Local Ethics Research Committee approval was obtained. All procedures performed in this study were in accordance with the ethical standards of the institutional research committee. This study complies with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures were approved by he Local Ethics Research Committee of the University Hospital Policlinico \u201cG. Martino\u201d. The study was carried out in accordance with the World Medical Association\u2019s Declaration of Helsinki. No animals were used for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Written informed consent was obtained from the patients for publication of this case series.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}